Company profile
Cybin Inc. Common Stock
NASDAQ: HELP · Healthcare · Biotechnology
Canadian filerHQ Toronto, ONCIK 0001833141Reports USD
#1 of 1,418 Healthcare companies by revenue
EA Score
——FH —DQ —GM —SS 58
v0.1 · 5/100 weight · pillars only
↑ balance-sheet leverage, Altman-Z · ↓ filing timeliness, listing tenure
Methodology →Revenue TTM
$1.3M
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$81.3M
Employees
100
as of 2026-08-13
Market cap
$712.2M
as of 2026-08-13
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Net income-$81.3M-113.1M CAD2025
Total assets$179.9M258.6M CAD2025
Liabilities$6.3M7.9M CAD2022
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Cybin Inc. Common Stock’s financial profile?
Cybin Inc. Common Stock earned -$81.3M in FY2025 net income.
Peers · Healthcare
Bright Minds Biosciences Inc.——SpyGlass Pharma, Inc. Common Stock——BridgeBio Oncology Therapeutics Inc.——Jade Biosciences, Inc.——Tectonic Therapeutic, Inc.——Adlai Nortye Ltd.——Key facts
CEOMichael Halstead
SectorHealthcare
IndustryBiotechnology
HeadquartersToronto, ON
ExchangeNASDAQ: HELP
Employees100
IPO date2019-09-13
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.